Compare Keurig Dr Pepper Inc. Common Stock (KDP) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keurig Dr Pepper Inc. Common Stock vs Tango Therapeutics Inc. — how do they compare? Keurig Dr Pepper Inc. Common Stock trades at $33.28 (market cap $44.44B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Keurig Dr Pepper Inc. Common Stock is far larger — about 11.9× Tango Therapeutics Inc.'s market cap, and Keurig Dr Pepper Inc. Common Stock pays a 2.82% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Keurig Dr Pepper Inc. Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| KDP | TNGX | |
|---|---|---|
Market Cap | $44.44B | $3.75B |
Volume | 11,656,694 | 9,619,106 |
Sector | Consumer Staples | Health |
52-Week High | $33.50 | $32.90 |
52-Week Low | $25.31 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $72.91B | $2.77B |
Dividend Yield | 2.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keurig Dr Pepper (KDP) trades at $32.66, down 0.27% today, with strong technical momentum showing bullish moving averages and key support at $32. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.57 beating expectations of $0.537, and maintains a healthy 49.39% gross margin. Recent news highlights the planned 2027 business split and beverage innovation pipeline as growth catalysts.
KDP presents a favorable investment case with 62% analyst buy ratings and a $37.75 consensus price target offering 15% upside. However, risks include elevated debt levels at 74.2% of market cap and potential execution challenges with the upcoming corporate restructuring. The stock's current valuation at 32.99 P/E requires continued earnings growth to justify further appreciation.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keurig Dr Pepper Inc. Common Stock
Keurig Dr Pepper produces and distributes coffee, soft drinks, juices, and other beverages. It also operates the Keurig single-serve coffee system.
Read more on KDP →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
